Castle Creek Arbitrage’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-163,847
Closed -$1.63M 708
2021
Q3
$1.63M Hold
163,847
0.09% 224
2021
Q2
$1.62M Hold
163,847
0.09% 239
2021
Q1
$1.63M Hold
163,847
0.1% 225
2020
Q4
$1.77M Buy
163,847
+88,000
+116% +$906K 0.11% 139
2020
Q3
$779K Buy
+75,847
New +$788K 0.06% 102

Other funds holding STLN

Castle Creek Arbitrage's STLN Position: Q4 2021 in Review

Castle Creek Arbitrage sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 163,847 shares — an estimated $1.63M sold.

Castle Creek Arbitrage first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $1.77M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Castle Creek Arbitrage reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Castle Creek Arbitrage sold 163,847 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $1.63M.
  • Castle Creek Arbitrage first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Castle Creek Arbitrage's Starling Oncology Institute, Inc. Common Stock position peaked at $1.77M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Castle Creek Arbitrage's 13F filing for Q4 2021, filed 14 Feb 2022.